Gene Expression, Meditative Movement, and Emotional Distress (GME)

Sponsor
Arizona State University (Other)
Overall Status
Unknown status
CT.gov ID
NCT04213872
Collaborator
Pomona Valley Hospital Medical Center (Other), Children's Hospital Los Angeles (Other)
27
1
1
31
0.9

Study Details

Study Description

Brief Summary

Study Title: Gene Expression, Meditative Movement and Emotional Distress (GME)

Background and Objectives:

Breast cancer survivors (BCS) often report decrements in cognitive functioning. Cognitive impairment (CI) is generally understood as resulting from chemotherapy or radiation, but may also result from chronic emotional distress experienced by breast cancer patients and survivors. Meditation and exercise are both known to reduce stress, with growing evidence for the potential of each to also improve cognitive functioning in cancer patients and survivors. A Meditative Movement (MM) program (Qigong/Tai Chi Easy) offers the potential of combining both benefits of meditation and exercise for breast cancer survivors. This is a pilot study, testing the MM program to effect changes in cognitive functioning and associated symptoms/conditions such as anxiety, depression, sleep quality and using gene expression factors as biomarkers to potentially measure the molecular signature of these changes. Forty BCS will be consented and assigned to an intensive eight week MM program. Cognitive functioning and associated symptoms/conditions will be assessed before and after the 8-week MM program to examine the participants' behaviors and symptoms. Peripheral blood samples will be collected before and after the 8-week MM program and will be analyzed for gene expression changes. If successful, this study may provide preliminary data for a full powered randomized control trial if results show promise in the psycho-behavioral outcomes and genomic expression results.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Meditative Movement
N/A

Detailed Description

This is a single-group pilot study on the effects of 8 weeks of MM practice on changes in cognitive function, anxiety, sleep quality, depression, and selected gene expression factors. Forty BCS will be consented and assigned to an intensive eight-week MM program. The forty BCS will be nonrandomly assigned to the eight-week MM program with no control group. The forty BCS will be organized in cohorts of 10 for the 8-week MM program. Cognitive functioning and associated symptoms/conditions data will be collected before and after the 8-week MM program to assess cognitive functioning, anxiety, depression, and sleep-quality. This data will be analyzed using the IBM SPSS Statistics program. Peripheral blood samples will be collected before and after the 8-week MM program. The gene expression data will be processed and analyzed by the bioinformatics team at the Single-Cell, Sequencing, and CyTOF Core (SC2), Children's Hospital Los Angeles (CHLA), Los Angeles.

Endpoints:

Endpoint 1: The Meditative Movement (MM) program will affect cognitive impairment.

Endpoint 2: The Meditative Movement (MM) program will affect anxiety, depression, and sleep quality.

Endpoint 3: The MM program will affect gene expression associated with cognitive impairment and associated symptoms.

Study Design

Study Type:
Interventional
Actual Enrollment :
27 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
This is a single-group nonrandomized pilot study on the effects of 8 weeks of MM program on changes in cognitive function, anxiety, sleep quality, depression, and selected gene expression factors.This is a single-group nonrandomized pilot study on the effects of 8 weeks of MM program on changes in cognitive function, anxiety, sleep quality, depression, and selected gene expression factors.
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Gene Expression, Meditative Movement, and Emotional Distress (GME): A Pilot Study
Actual Study Start Date :
Jul 17, 2017
Actual Primary Completion Date :
Nov 15, 2018
Anticipated Study Completion Date :
Feb 15, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Meditative Movement (MM)

The Meditative Movement (Qigong/Tai Chi Easy) program will be 8 weeks in duration with sessions once a week. Each session is approximately one hour. The PI will lead the MM sessions. The PI and the CRC will maintain contact with the MM group during the 8 weeks by telephone or in person.

Behavioral: Meditative Movement
The Meditative Movement program is a blend of meditation and exercise based on Tai Chi and Qigong.

Outcome Measures

Primary Outcome Measures

  1. Changes in Cognitive Functioning [The research participants will complete the FACT-COG pre- and post-8 week intervention within two weeks prior to and subsequent to the 8-week intervention. The PI will administer WAIS-III measures within two weeks before and after 8-week intervention.]

    Cognitive function self-report will be assessed using the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-COG), 33 items, validated, including 3 subscales including perceived cognitive impairment (PCI), perceptions of effects of cognitive function on quality of life (PCQOL), and perceived cognitive abilities (CA) Two brief measures of attention/working memory from the Wechsler Adult Intelligence Scale-Third Edition (WAIS-III) assess CP: Digit Span and Letter-Number Sequencing, with reliability ratings of .90 and .82 respectively.

Secondary Outcome Measures

  1. Changes in BDNF Expression (associated with learning and memory). [Blood samples will be collected within two weeks before and after 8 week intervention.]

    RNA sequencing: Sequencing libraries will be prepared from previously purified RNA using the Illumina TruSeq Stranded mRNA Library Prep kit following the manufacturer's instructions. Sequencing will be performed on a NextSeq 500 platform using 2×75bp chemistry. Data analysis: Quality control and adapter trimming will be performed using trim galore (v0.4.2) with default parameters. Reads will be aligned to the GRCh38 reference genome and transcriptome using HISAT2 (v2.1.0), and transcript quantification will be performed using featureCounts (v1.5.1). Differential expression analysis will be performed using the 'DESeq2' R package (v1.16.1), and a rank score calculated as -log10(q-val)*sign (log2 FoldChange) will be used as input to the GSEA Preranked tool for pathway analysis.

Other Outcome Measures

  1. Changes in anxiety, depression, and sleep quality. [The research participants will complete these measures pre- and post-8 week intervention within two weeks prior to and subsequent to the 8-week intervention.]

    Profile of Mood States Short Form (POMS-SF): 37 items, adjectives scored on a 5-point Likert scale. The POMS is one of the most frequently used and validated scales in studies of psychosocial interventions with BCSs. POMS consists of the Total Mood Disturbance (TMD) dimensions (tension-anxiety; depression-dejection; anger-hostility; confusion-bewilderment. The Pittsburgh Sleep Quality Index (PSQI): 19 items assess sleep, including subscales for subjective sleep quality, sleep latency, sleep duration, sleep disturbance, habitual sleep efficiency, daytime dysfunction and use of sleep medications.

  2. Changes in BDNF gene expression associated with changes in NF-kB and TP53 gene expression (associated with inflammation and tumor suppression). [Blood samples will be collected within two weeks before and after 8 week intervention.]

    RNA sequencing: Sequencing libraries will be prepared from previously purified RNA using the Illumina TruSeq Stranded mRNA Library Prep kit following the manufacturer's instructions. Sequencing will be performed on a NextSeq 500 platform using 2×75bp chemistry. Data analysis: Quality control and adapter trimming will be performed using trim galore (v0.4.2) with default parameters. Reads will be aligned to the GRCh38 reference genome and transcriptome using HISAT2 (v2.1.0), and transcript quantification will be performed using featureCounts (v1.5.1). Differential expression analysis will be performed using the 'DESeq2' R package (v1.16.1), and a rank score calculated as -log10(q-val)*sign (log2 FoldChange) will be used as input to the GSEA Preranked tool for pathway analysis.

Eligibility Criteria

Criteria

Ages Eligible for Study:
45 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Female patients diagnosed with breast cancer, Stage 0- III

  • Between 6 months and 5 years past primary treatment

  • 45 years of age and older

  • Post-menopausal

  • Speak or understand English

Exclusion Criteria:
  • Women who are unable to stand (e.g., wheelchair or walker bound)

  • Patients who are too weak or ill

  • Women on antibiotics.

  • Working night shift

  • Anemia

  • Uncontrolled diabetes

Contacts and Locations

Locations

Site City State Country Postal Code
1 Robert and Beverly Lewis Family Cancer Care Center Pomona California United States 91767

Sponsors and Collaborators

  • Arizona State University
  • Pomona Valley Hospital Medical Center
  • Children's Hospital Los Angeles

Investigators

  • Principal Investigator: Francisco V Munoz, Ph.D., Arizona State University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Arizona State University
ClinicalTrials.gov Identifier:
NCT04213872
Other Study ID Numbers:
  • GME Study
First Posted:
Dec 30, 2019
Last Update Posted:
Dec 30, 2019
Last Verified:
Dec 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Arizona State University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 30, 2019